טוען...
A Novel Adenylyl Cyclase Type 5 Inhibitor That Reduces Myocardial Infarct Size Even When Administered After Coronary Artery Reperfusion
We developed a novel adenylyl cyclase type 5 (AC5) inhibitor, C90, that reduces myocardial infarct size even when administered after coronary reperfusion. This is key, since it is not practical to administer a drug to a patient with myocardial infarction before revascularization, and is one reason w...
שמור ב:
| הוצא לאור ב: | J Mol Cell Cardiol |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6103820/ https://ncbi.nlm.nih.gov/pubmed/29800555 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.yjmcc.2018.05.014 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|